Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16237581 | 0.98 | ALDH1A1 (0.30) | MAPT | |
| SCHEMBL11863377 | 0.93 | — | — | |
| SCHEMBL12110858 | 0.89 | KDM4E (0.31) | — | |
| SCHEMBL11981737 | 0.89 | KDM4E (0.31) | — | |
| SCHEMBL114258 | 0.83 | TSHR (0.35) | — | |
| SCHEMBL15786373 | 0.83 | TSHR (0.35) | — | |
| SCHEMBL18537682 | 0.83 | TSHR (0.35) | — | |
| SCHEMBL15780501 | 0.83 | TSHR (0.35) | — | |
| SCHEMBL18807102 | 0.83 | TSHR (0.35) | — | |
| SCHEMBL11485502 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111420068-B | Polyethylene glycol-dendritic polylysine/anhydride-cisplatin compound and preparation method and application thereof | 浙江大学 | 2021-11-09 | — | — | CN | claimed |
| CN-111420068-A | Polyethylene glycol-dendritic polylysine/anhydride-cisplatin compound and preparation method and application thereof | 浙江大学 | 2020-07-17 | — | — | CN | claimed |
| CN-110755639-A | Polyethylene glycol-dendritic polylysine/anhydride-cisplatin compound and preparation method and application thereof | 浙江大学 | 2020-02-07 | — | — | CN | claimed |
| CN-111420068-B | Polyethylene glycol-dendritic polylysine/anhydride-cisplatin compound and preparation method and application thereof | 浙江大学 | 2021-11-09 | — | — | CN | disclosed |
| CN-111420068-A | Polyethylene glycol-dendritic polylysine/anhydride-cisplatin compound and preparation method and application thereof | 浙江大学 | 2020-07-17 | — | — | CN | disclosed |
| CN-110755639-A | Polyethylene glycol-dendritic polylysine/anhydride-cisplatin compound and preparation method and application thereof | 浙江大学 | 2020-02-07 | — | — | CN | disclosed |
| EP-2997046-B1 | CELLULOSE ETHERS ESTERIFIED WITH DICARBOXYLIC ACIDS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-9890221-B2 | Cellulose ethers esterified with dicarboxylic acid | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-02-13 | — | — | US | disclosed |
| CN-105164162-B | The cellulose ether being esterified with dicarboxylic acids | 陶氏环球技术有限责任公司 | 2017-11-28 | — | — | CN | disclosed |
| US-20160289344-A1 | CELLULOSE ETHERS ESTERIFIED WITH DICARBOXYLIC ACID | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2016-10-06 | — | — | US | disclosed |
| US-9376413-B1 | Succinic anhydrides from epoxides | CORNELL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| EP-1599496-A2 | HEPATITIS C INHIBITOR PEPTIDE ANALOGS | Boehringer Ingelheim International GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-6908901-B2 | Hepatitis C inhibitor peptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2005-06-21 | — | — | US | disclosed |
| WO-2004101602-A2 | HEPATITIS C INHIBITOR PEPTIDE ANALOGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| US-20040224900-A1 | Hepatitis C inhibitor peptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
| US-20040224900-A1 | Hepatitis C inhibitor peptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
| US-20040224900-A1 | Hepatitis C inhibitor peptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
| US-6228986-B1 | REDUCTIVE ALKYLATION OF ALPHA-NITROGEN OF RESIN-BOUND PROTECTED LYSINE, ACYLATION WITH PROTECTED-AMINO ACID, DEBLOCKING, ACYLATING WITH SUBSTITUTED SUCCINIC ANHYDRIDE, REMOVING PROTECTION FROM LYSINE, THEN CYCLIZATION | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-05-08 | — | — | US | disclosed |
| US-4725373-A | CORROSION RESISTANCE FOR METAL TOOLS AND EQUIPMENT USED IN OIL AND GAS WELLS | THE DOW CHEMICAL COMPANY (US) | 1988-02-16 | — | — | US | disclosed |
| US-3960937-A | REACTION PRODUCT OF PETROLEUM SULFONIC ACIDS, POLYAMINES, CYCLIC ANHYDRIDES | PHILLIPS PETROLEUM COMPANY (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224900-A1 | Hepatitis C inhibitor peptide analogs | RNASE1, HAVCR2, CTRL | MAPT 4574/4885CHRM2 4877/4885CHRM1 4777/4885 |
| US-20160289344-A1 | CELLULOSE ETHERS ESTERIFIED WITH DICARBOXYLIC ACID | SCO2, SUCNR1, MCCC2 | MAPT 1794/4885CHRM2 6/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.